PRTA: Prothena Corp. Plc
About
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Current Value
$14.051 Year Return
Current Value
$14.051 Year Return
Key Details
Market Cap
$756.01M
P/E Ratio
-5.66
1Y Stock Return
-56.52%
1Y Revenue Growth
-5.41%
Dividend Yield
0.00%
Price to Book
1.4
Strategies that include PRTA
Stock's related to PRTA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 50.31% | $2.09B | -9.52% | 0.00% |
| DNLI | 50.06% | $3.50B | +33.66% | 0.00% |
| RXRX | 45.94% | $1.80B | -4.13% | 0.00% |
| PGEN | 45.91% | $228.91M | -28.00% | 0.00% |
| OFLX | 45.79% | $509.01M | -24.87% | 2.66% |
| KYMR | 45.66% | $2.77B | +125.95% | 0.00% |
| ALEC | 45.43% | $377.04M | -19.46% | 0.00% |
| NTLA | 45.21% | $1.44B | -50.35% | 0.00% |
| RGNX | 44.71% | $473.65M | -51.96% | 0.00% |
| CFB | 44.41% | $842.06M | +48.26% | 0.00% |
| DVAX | 44.40% | $1.58B | -11.37% | 0.00% |
| HBNC | 44.23% | $788.62M | +64.30% | 3.57% |
| TRST | 44.03% | $691.41M | +34.26% | 3.98% |
| TMP | 43.96% | $1.07B | +39.83% | 3.29% |
| ACLX | 43.64% | $4.74B | +69.19% | 0.00% |
| PFC | 43.62% | $990.65M | +38.69% | 4.50% |
| WASH | 43.24% | $628.84M | +39.42% | 5.76% |
| GBIO | 43.13% | $92.84M | +20.87% | 0.00% |
| NFBK | 43.03% | $557.75M | +32.52% | 3.98% |
| HTBK | 42.85% | $645.52M | +24.17% | 4.92% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAPR | 0.01% | $839.37M | +532.19% | 0.00% |
| FTNT | -0.10% | $69.59B | +72.67% | 0.00% |
| VHC | 0.14% | $19.06M | -38.36% | 0.00% |
| SNY | -0.14% | $120.34B | +3.11% | 4.25% |
| GIS | 0.24% | $34.85B | -2.91% | 3.78% |
| SBUX | 0.24% | $111.45B | -5.15% | 2.37% |
| CAH | 0.24% | $28.64B | +12.14% | 1.70% |
| KNTK | -0.31% | $3.59B | +67.71% | 5.02% |
| PEP | -0.34% | $215.02B | -6.60% | 3.35% |
| HQY | 0.39% | $8.97B | +52.15% | 0.00% |
| UUU | -0.47% | $4.97M | -41.89% | 0.00% |
| EDU | -0.49% | $9.06B | -22.20% | 0.00% |
| CLX | -0.50% | $20.81B | +20.66% | 2.88% |
| EZPW | 0.53% | $655.76M | +45.24% | 0.00% |
| DOGZ | -0.57% | $614.77M | +1,372.26% | 0.00% |
| CYCN | 0.59% | $4.77M | -16.19% | 0.00% |
| TEO | -0.60% | $1.69B | +87.97% | 0.00% |
| IMNN | 0.64% | $10.02M | -22.89% | 0.00% |
| DKL | 0.70% | $2.03B | -18.84% | 10.94% |
| HIHO | 0.75% | $8.63M | 0.00% | 6.12% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CME | -14.28% | $82.76B | +9.21% | 1.98% |
| CYD | -13.41% | $364.46M | -2.94% | 4.26% |
| LPLA | -13.34% | $23.55B | +38.13% | 0.38% |
| MCK | -12.97% | $78.15B | +35.51% | 0.42% |
| EDR | -12.46% | $9.01B | +19.26% | 0.82% |
| TCTM | -11.57% | $8.10M | -42.99% | 0.00% |
| COR | -11.55% | $47.48B | +21.20% | 0.86% |
| HUSA | -11.07% | $16.69M | -11.56% | 0.00% |
| STG | -10.81% | $35.67M | +7.92% | 0.00% |
| CBOE | -10.37% | $21.46B | +15.84% | 1.11% |
| GHI | -9.11% | $272.26M | -27.60% | 12.75% |
| PGR | -8.73% | $149.10B | +57.29% | 0.45% |
| CHD | -8.46% | $27.18B | +19.50% | 1.03% |
| SAVA | -8.37% | $1.35B | +25.50% | 0.00% |
| TW | -7.53% | $28.66B | +42.39% | 0.29% |
| ZCMD | -7.32% | $2.80M | -88.67% | 0.00% |
| MNR | -6.32% | $1.66B | -10.71% | 15.90% |
| PULM | -5.91% | $19.83M | +202.98% | 0.00% |
| WTW | -5.54% | $30.98B | +26.60% | 1.13% |
| WM | -5.01% | $87.92B | +27.58% | 1.34% |
ETF's related to PRTA
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 60.33% | $6.58B | 0.35% |
| PBE | 57.41% | $258.53M | 0.58% |
| GNOM | 56.55% | $70.59M | 0.5% |
| ARKG | 56.16% | $1.13B | 0.75% |
| IWC | 55.04% | $933.99M | 0.6% |
| IBB | 54.85% | $6.66B | 0.45% |
| RSPA | 54.06% | $273.87M | 0% |
| VTWO | 53.06% | $12.38B | 0.1% |
| IWM | 53.04% | $75.73B | 0.19% |
| IWN | 52.36% | $13.17B | 0.24% |
| ESML | 52.07% | $1.90B | 0.17% |
| NUSC | 51.72% | $1.27B | 0.31% |
| PTH | 51.63% | $143.31M | 0.6% |
| IWO | 51.59% | $12.56B | 0.24% |
| FBT | 51.29% | $1.11B | 0.56% |
| GSSC | 51.03% | $529.86M | 0.2% |
| SMMD | 50.74% | $1.24B | 0.15% |
| PRFZ | 50.72% | $2.65B | 0.39% |
| ISCG | 50.66% | $640.00M | 0.06% |
| FYX | 50.42% | $959.00M | 0.6% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBTE | -0.32% | $1.70B | 0.07% |
| XHLF | -0.34% | $874.27M | 0.03% |
| HDRO | -0.39% | $164.26M | 0.3% |
| AGZD | -0.44% | $142.76M | 0.23% |
| CANE | -0.50% | $17.72M | 0.29% |
| KRBN | 0.94% | $242.47M | 0.85% |
| DBA | -1.00% | $755.88M | 0.93% |
| CSHI | 1.08% | $482.85M | 0.38% |
| SGOV | 1.21% | $27.53B | 0.09% |
| FMF | -1.53% | $244.61M | 0.95% |
| WEAT | 1.56% | $120.27M | 0.28% |
| HIGH | -1.59% | $302.78M | 0.51% |
| BSCO | 1.76% | $2.35B | 0.1% |
| DBMF | 1.94% | $1.02B | 0.85% |
| BOXX | -1.95% | $4.43B | 0.1949% |
| TBIL | -2.17% | $4.38B | 0.15% |
| XBIL | 2.59% | $637.70M | 0.15% |
| SHV | 3.19% | $18.13B | 0.15% |
| DBE | 3.54% | $50.13M | 0.77% |
| BILZ | -3.64% | $563.02M | 0.14% |
News
Yahoo
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Yahoo
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Yahoo
Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
DUBLIN (AP) — Prothena Corp. PRTA) on Tuesday reported a loss of $59 million in its third quarter. The Dublin-based company said it had a loss of $1.10 per share.
Yahoo
DUBLIN, November 12, 2024--Prothena today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.
Yahoo
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.